Who owns Vor Biopharma Inc?
- Ticker: VOR
- CUSIP Number: 929033108
Tip: Access positions for across all investors
Analyze quarterly positions in Vor Biopharma with up to 7 years of data, all consolidated into one spreadsheet
Download as csv
Download as Excel
Top investors of Vor Biopharma stock
Who bought or sold Vor Biopharma Inc this quarter?
| Fund or Company Name | Shares Held | Valued At | Change in Shares | As Of | Actions |
|---|---|---|---|---|---|
| RA Capital Management | 23M | $51M | 0% | Dec 2023 |
|
| Paradigm Biocapital Advisors | 6.5M | $15M | 0% | Dec 2023 |
|
| 5AM Venture Management | 6.4M | $14M | 0% | Dec 2023 |
|
| Laurion Capital Management | 3.2M | $7.2M | 0% | Dec 2023 |
|
| Artal Group | 2.3M | $5.3M | -13% | Dec 2023 |
|
| Vanguard Group | 1.7M | $3.9M | 2% | Dec 2023 |
|
| Sarissa Capital Management | 618k | $1.4M | 0% | Dec 2023 |
|
| MAI Wealth Advisors | 357k | $804k | 100% | Dec 2023 |
|
| Exchange Traded Concepts | 154k | $366k | 157% | Mar 2024 |
|
| Bank of New York Mellon | 108k | $244k | 0% | Dec 2023 |
|
| Charles Schwab Investment Management | 104k | $234k | 0% | Dec 2023 |
|
| Bank of America Corporation | 54k | $121k | 73% | Dec 2023 |
|
| Barclays | 52k | $117k | 621% | Dec 2023 |
|
| LMR Partners | 51k | $115k | 5% | Dec 2023 |
|
| Rhumbline Advisers | 43k | $97k | -4% | Dec 2023 |
|
| Goldman Sachs Group | 38k | $86k | 50% | Dec 2023 |
|
| UBS Group | 38k | $85k | 132% | Dec 2023 |
|
| Citadel Advisors | 34k | $77k | 204% | Dec 2023 |
|
| Deutsche Bank Aktiengesellschaft | 32k | $72k | 100% | Dec 2023 |
|
| Bourgeon Capital Management | 30k | $70k | 0% | Mar 2024 |
|
| Jpmorgan Chase & Co | 25k | $55k | -3% | Dec 2023 |
|
| New York State Common Retirement Fund | 22k | $48k | -1% | Dec 2023 |
|
| SG Americas Securities | 21k | $48k | 23% | Dec 2023 |
|
| Dimensional Fund Advisors | 21k | $46k | -35% | Dec 2023 |
|
| American International | 19k | $42k | 0% | Dec 2023 |
|
| Chicago Partners Investment | 17k | $41k | -4% | Dec 2023 |
|
| Jane Street | 17k | $38k | 100% | Dec 2023 |
|
| Royal Bank of Canada | 14k | $32k | 100% | Dec 2023 |
|
| Grimes & Company | 14k | $34k | 3% | Mar 2024 |
|
| Wells Fargo & Company | 12k | $26k | 25% | Dec 2023 |
|
| United Bank | 11k | $25k | 100% | Dec 2023 |
|
| Wexford Capital | 10k | $23k | 100% | Dec 2023 |
|
| Citigroup | 5.7k | $13k | 31772% | Dec 2023 |
|
| Legal & General Group | 3.6k | $8.1k | 0% | Dec 2023 |
|
| Summit Investment Advisors | 3.1k | $7.0k | 0% | Dec 2023 |
|
| Lazard Asset Management | 2.1k | $0 | -4% | Dec 2023 |
|
| Amalgamated Bank | 1.3k | $3.0k | -61% | Mar 2024 |
|
| Simplex Trading | 797.00 | $999.995900 | 100% | Dec 2023 |
|
| Eagle Bay Advisors | 150.00 | $337.995000 | 0% | Dec 2023 |
|
| NISA Investment Advisors | 45.00 | $100.998000 | 0% | Dec 2023 |
|
| CWM | 31.00 | $0 | 100% | Mar 2024 |
|
Who sold out of Vor Biopharma?
| Fund or Company Name | Date Sold | Shares Held | Valued At |
|---|---|---|---|
| Baker Bros. Advisors | Sep 2023 | 634k | $1.3M |
| Squarepoint Ops | Sep 2023 | 16k | $33k |
| Gladius Capital Management | Sep 2023 | 10k | $21k |